NAPA Reauthorization Act

To extend the National Alzheimer's Project. 1. Short title This Act may be cited as the NAPA Reauthorization Act 2. Extension of project Section 2 of the National Alzheimer's Project Act ( 42 U.S.C. 11225 (1) in subsection (c)— (A) in paragraph (2), by striking and coordination of on, and coordination of, (B) in paragraph (4)— (i) by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and (ii) by inserting before subparagraph (B), as so redesignated, the following: (A) promotion of healthy aging and reduction of risk factors for Alzheimer's; ; (C) in paragraph (5), by striking ; and (D) by redesignating paragraph (6) as paragraph (7); and (E) by inserting after paragraph (5) the following: (6) provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and ; (2) in subsection (d)(2)— (A) by inserting , across public and private sectors, Nation's progress (B) by inserting , including consideration of public-private collaborations, as appropriate (3) in subsection (e)— (A) in paragraph (2)— (i) in subparagraph (A), by adding at the end the following: (xi) A designee of the Department of Justice. (xii) A designee of the Federal Emergency Management Agency. (xiii) A designee of the Social Security Administration. (xiv) A designee of the Office of Management and Budget. (xv) 1 or more other designees of the Department of Health and Human Services, as determined by the Secretary of Health and Human Services. ; and (ii) in subparagraph (B)— (I) in clause (v)— (aa) by striking 2 researchers 3 researchers (bb) by striking ; and , including at least one researcher with demonstrated experience in recruitment and retention of diverse cohorts of trial participants; (II) in clause (vi), by striking the period and inserting ; and (III) by adding at the end the following: (vii) an individual with a diagnosis of Alzheimer's disease. ; (B) in paragraph (5)— (i) in subparagraph (A)— (I) by striking an initial evaluation annual evaluations (II) by striking research, clinical research, risk reduction, public health, clinical (ii) in subparagraph (B), by striking initial (iii) in subparagraph (C)— (I) in the matter preceding clause (i), by striking initial (II) in clause (ii), by inserting and reduce disparities (iv) in subparagraph (D), by striking annually thereafter, an evaluation annual evaluations (C) in paragraph (6), by striking 2025 2035 (4) in subsection (g)(3)(A)(ii), by inserting and reduce disparities (5) in subsection (h), by striking 2025 2035 1. Short title This Act may be cited as the NAPA Reauthorization Act 2. Extension of project Section 2 of the National Alzheimer's Project Act ( 42 U.S.C. 11225 (1) in subsection (c)— (A) in paragraph (2), by striking and coordination of on, and coordination of, (B) in paragraph (4)— (i) by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and (ii) by inserting before subparagraph (B), as so redesignated, the following: (A) promotion of healthy aging and reduction and mitigation of risk factors for Alzheimer's; ; (C) in paragraph (5)— (i) by inserting and other underserved populations, including individuals with developmental disabilities such as Down syndrome, ethnic and racial populations (ii) by striking ; and (D) by redesignating paragraph (6) as paragraph (7); and (E) by inserting after paragraph (5) the following: (6) provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and ; (2) in subsection (d)(2)— (A) by inserting , across public and private sectors, Nation's progress (B) by inserting , including consideration of public-private collaborations, as appropriate (3) in subsection (e)— (A) in paragraph (2)— (i) in subparagraph (A), by adding at the end the following: (xi) A designee of the Department of Justice. (xii) A designee of the Federal Emergency Management Agency. (xiii) A designee of the Social Security Administration. (xiv) 2 or more other designees, as determined by the Secretary of Health and Human Services, at least one of whom has expertise in risk factors associated with the development or the progression of Alzheimer's. ; and (ii) in subparagraph (B)— (I) in the matter preceding clause (i), by striking 12 15 (II) in clause (v)— (aa) by striking 2 researchers 3 researchers (bb) by striking ; and , including at least one researcher with demonstrated experience in recruitment and retention of diverse cohorts of trial participants; (III) in clause (vi), by striking the period and inserting a semicolon; and (IV) by adding at the end the following: (vii) 1 individual with a diagnosis of Alzheimer's disease; and (viii) 1 representative from a historically underserved population whose lifetime risk for developing Alzheimer's is markedly higher than that of other populations. ; (B) in paragraph (5)— (i) in subparagraph (A)— (I) by striking an initial evaluation annual evaluations (II) by striking research, clinical research, risk reduction, public health, clinical (ii) in subparagraph (B), by striking initial (iii) in subparagraph (C)— (I) in the matter preceding clause (i), by striking initial (II) in clause (ii), by inserting and reduce disparities (iv) in subparagraph (D), by striking annually thereafter, an evaluation annual evaluations (C) in paragraph (6), by striking 2025 2035 (4) in subsection (g)(3)(A)(ii), by inserting and reduce disparities (5) in subsection (h), by striking 2025 2035 July 27, 2023 Reported with an amendment

Summary: NAPA Reauthorization Act This bill extends through 2035 and makes other changes to the National Alzheimer's Project. This project supports coordination of federal planning, programs, and other efforts to address Alzheimer's disease and related dementias. In particular, the bill incorporates a focus on promoting healthy aging and reducing risk factors associated with cognitive decline. The bill also expands the Advisory Council on Alzheimer's Research, Care, and Services to include additional members, such as (1) a researcher with experience recruiting and retaining diverse clinical trial participants, (2) an individual diagnosed with Alzheimer's disease, and (3) representatives from additional federal agencies (e.g., the Department of Justice).